Clinical Research Directory
Browse clinical research sites, groups, and studies.
18F-DOPA II - PET Imaging Optimization
Sponsor: University of Alberta
Summary
A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism. 2. Pediatric patients (less than 18 years old) with neuroblastoma. 3. Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor. 4. Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia. 5. Pediatric (less than 18 years old) or Adult patients (18 or older) with brain tumors. Image optimization (the primary study objective) and gallbladder activity pattern (the secondary objective) will be evaluated.
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
800
Start Date
2021-01-20
Completion Date
2027-12
Last Updated
2026-02-09
Healthy Volunteers
No
Conditions
Interventions
18F-DOPA
All participants will receive an intravenous injection of 18F-DOPA (4MBq/kg; minimum 110 MBq, maximum 600 MBq) for this study
Furosemide Injection
Some participants will receive an intravenous injection of furosemide (40mg, single dose)
Locations (1)
WC Mackenzie Health Science Centre / University of Alberta Hospital
Edmonton, Alberta, Canada